SCHEMBL5539864

SCHEMBL5539864

Nc1ccccc1CCOC=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDPS P14324 1/20 0.36
SIGMAR1 Q99720 2/20 0.35
ALDH1A1 P00352 7/20 0.33
HSD17B10 Q99714 5/20 0.33
SMN1; SMN2 Q16637 4/20 0.33
HPGD P15428 3/20 0.33
CYP3A4 P08684 2/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
TSHR P16473 2/20 0.33
ALOX15 P16050 1/20 0.33
CASP1 P29466 1/20 0.33
CASP7 P55210 1/20 0.33
TP53 P04637 1/20 0.33
GLA P06280 1/20 0.33
MAPK1 P28482 1/20 0.33
HIF1A Q16665 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
MEN1 O00255 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5542907 0.85 CD44 (0.32)
Propylformate SCHEMBL28281240 0.81 CYP1A2 (0.41) FDPSALDH1A1HSD17B10HPGDL3MBTL1
SCHEMBL177344 0.80 FDPS (0.38) FDPSALDH1A1HSD17B10SMN1; SMN2CYP3A4
Ethoxycarbonyl Group SCHEMBL28280211 0.79 ALDH1A1 (0.38) FDPSSIGMAR1ALDH1A1HSD17B10L3MBTL1
SCHEMBL2096285 0.78 TAAR1 (0.52) ALDH1A1HPGDTAAR1IDO1
SCHEMBL12028431 0.78 L3MBTL1 (0.39) ALDH1A1SMN1; SMN2HPGDL3MBTL1KDM4E
SCHEMBL30452110 0.78 GAA (0.35) ALDH1A1TSHRCASP1CASP7TP53
SCHEMBL15328757 0.78 GAA (0.35) ALDH1A1TSHRCASP1CASP7TP53
SCHEMBL9850277 0.77 SMN1; SMN2 (0.41) FDPSSIGMAR1ALDH1A1HSD17B10SMN1; SMN2
Ethoxycarbonyl Group SCHEMBL28870102 0.77 ALDH1A1 (0.42) FDPSALDH1A1HSD17B10SMN1; SMN2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 FDPS 1781/4885SIGMAR1 234/4885ALDH1A1 355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.